Celestial - Suzy QFX Harli-Tsu BX1 M: A Comprehensive Strain Guide

Overview and Naming

Celestial - Suzy QFX Harli-Tsu BX1 M is a purpose-bred, CBD-dominant cannabis line designed for clean, functional relief and consistent chemotype expression. The name signals its core components: a Suzy Q cross to Harli-Tsu, followed by a single backcross (BX1) toward the Harli-Tsu side, with the “M” indicating a selected male used in the breeding work.

This article focuses on the phenotype and cultivation characteristics most growers will encounter when working from seed populations or verified cuts derived from this line. In practical terms, expect a Type III chemotype (CBD-dominant) with a very high CBD:THC ratio, moderate vigor, and a terpene profile anchored by pine, pepper, wood, and delicate citrus.

While live_info is not provided and strain data evolves with each breeding release, the context_details clearly establish the target as Celestial - Suzy QFX Harli-Tsu BX1 M. Accordingly, the guidance below synthesizes what is known about the parent cultivars, the BX1 breeding logic, and typical lab outcomes of comparable CBD lines to give growers and patients realistic expectations.

History

High-CBD cannabis breeding accelerated in the early 2010s when patients and caregivers in Northern California began selecting cultivars that delivered relief with minimal intoxication. Harli-Tsu emerged from this movement as a standout CBD-rich variety, while Suzy Q gained a reputation for reliably low THC and a clear body feel.

Celestial - Suzy QFX Harli-Tsu BX1 M arises from that tradition, aiming to combine Suzy Q’s gentle body calm with Harli-Tsu’s durable CBD dominance and clean, pine-forward terpene stack. The backcross step was introduced to pull the progeny back toward Harli-Tsu’s chemotype and structural traits while retaining Suzy Q’s soothing organoleptics.

The “M” in the name is consequential historically because it reflects a breeder’s male selection, a decision that shapes how the line transmits cannabinosynthesis genes and terpenes to offspring. A strong CBDAS-dominant male improves odds of Type III expression in crosses, helping stabilize CBD-rich outcomes for both medical growers and hashmakers.

Genetic Lineage

The base cross is Suzy Q × Harli-Tsu, followed by one backcross (BX1) to Harli-Tsu, ultimately expressed as Suzy Q × (Harli-Tsu backcrossed once with Harli-Tsu). In shorthand, breeders often show this as Suzy Q × Harli-Tsu → BX1 to Harli-Tsu, then a selected male is identified as the “M” donor.

Suzy Q is widely reported as a CBD-dominant cultivar that frequently tests with THC below 1% and CBD often in the low-to-mid teens, sometimes reaching the high teens under optimized conditions. Harli-Tsu, a cross of Harlequin × Sour Tsunami, is historically known for CBD levels commonly in the 12–22% range with very low THC.

By backcrossing once to Harli-Tsu, breeders tilt progeny toward consistent CBD dominance and resin traits characteristic of Harli-Tsu. The male selection is critical: a CBDAS/CBDAS (BD/BD) male increases the probability of Type III outcomes when used for seed production or further hybridization.

Appearance

In vegetative growth, Celestial - Suzy QFX Harli-Tsu BX1 M typically presents medium internodal spacing, upright apical dominance, and well-angled lateral branching. Leaf morphology leans hybrid with slightly narrow leaflets during vigorous growth, reflecting sativa-leaning ancestry from Harlequin.

Under high-intensity light, plants often develop sturdy, spear-like colas with moderate density and abundant trichome coverage. Pistils are commonly cream-to-tangerine, maturing to amber hues near finish as calyxes swell.

Anthocyanin expression can appear in late flower under cool night temperatures (15–18°C), particularly on bracts and sugar leaves. The overall bud structure tends toward a balanced density that resists botrytis better than ultra-dense THC-dominant varieties, an asset for outdoor growers.

Aroma

The dominant aromatic impression is resinous pine and cedar shavings, supported by black pepper and dry wood. Secondary notes include sweet citrus zest, faint herbal mint, and a light diesel whisper inherited from the Sour Tsunami lineage.

Cracking cured flowers releases a terpene stack often led by beta-myrcene and alpha/beta-pinene with a caryophyllene-humulene backbone. When properly cured at 60/60 (60°F/60% RH) for 10–14 days, the bouquet becomes layered and persistent without grassy or chlorophyll notes.

Consumers often describe the nose as clean, forest-forward, and comfortingly familiar. Compared to many modern dessert-like terpene profiles, this one is utilitarian and soothing rather than confectionary.

Flavor

On inhalation, expect crisp pine and lemon-peel brightness over a dry, cedar-like wood tone. Mid-palate shifts toward cracked black pepper and herbal bitters, signaling caryophyllene alongside humulene and trace limonene.

The exhale tends to be smooth and lightly astringent, with a lingering, mint-adjacent coolness and faint diesel backnote. Vaporization at 180–195°C accentuates citrus and pine, while combustion brings forward pepper and wood.

Cannabinoid Profile

Celestial - Suzy QFX Harli-Tsu BX1 M is engineered for Type III expression, typically presenting CBD in the low-to-high teens with trace THC. In dialed-in indoor runs, growers can expect total CBD (CBD + 0.877 × CBDA) in the 12–18% range and total THC (THC + 0.877 × THCA) commonly between 0.2–0.8% by dry weight.

Some phenotypes may exceed 18% total CBD when pushed under strong PPFD and optimized mineral balance, though these outcomes are contingent on environment and phenotypic selection. CBD:THC ratios frequently land between 15:1 and 30:1, delivering noticeable body ease without intoxication for most users.

Minor cannabinoids are typically present at modest levels: CBG (as CBG + 0.877 × CBGA) often 0.3–1.0%, CBC 0.2–0.6%, and CBDV trace to 0.3% depending on cut and maturity. Decarboxylation efficiency matters for formulation; CBDA to CBD conversion follows the 0.877 mass-loss factor, so 18% CBDA decarbs to roughly 15.8% CBD.

Growers targeting hemp compliance should note that even CBD-dominant flowers can surpass the 0.3% delta-9 THC threshold post-harvest. Field compliance is typically based on total delta-9 THC at sampling, making timely testing (e.g., weeks 3–5 of flower) a crucial risk-management step.

Terpene Profile

Total terpene concentration often ranges 1.5–3.0% by dry weight in well-grown flowers, with exceptional phenotypes exceeding 3.0% under optimized cultivation. The dominant constituents are commonly beta-myrcene (0.4–0.8%), alpha/beta-pinene (0.2–0.5%), beta-caryophyllene (0.2–0.6%), and humulene (0.1–0.3%).

Supporting terpenes typically include limonene (0.1–0.3%), ocimene (0.05–0.2%), and faint terpinolene in certain Harlequin-leaning phenos. This ensemble yields the pine-wood-pepper-citrus signature associated with Suzy Q and Harli-Tsu descendants.

Functionally, myrcene and caryophyllene contribute to body relaxation and perceived anti-inflammatory effects, while pinene and limonene keep the headspace clear and alert. The overall effect is grounding yet functional, a hallmark of well-structured CBD aromatics.

Experiential Effects

Most users report a clear-headed, non-intoxicating calm within 5–10 minutes of inhalation, peaking at 20–30 minutes and lasting 1–2 hours. Body effects are characterized by gentle muscle ease, reduced tension, and a quieting of background discomfort.

Mood effects trend toward steadiness rather than euphoria, with some uplift credited to limonene and pinene synergy. Higher doses can become mildly sedating, especially in myrcene-forward phenotypes or when combined with evening routines.

Compared to THC-dominant cultivars, cognitive impairment is minimal at normal CBD doses, which is why many patients use this chemotype during daytime tasks. Individuals with very low THC tolerance should still start low and titrate slowly, as even 0.3–0.7% total THC can be perceptible to ultra-sensitive users.

Oral ingestion produces a slower onset (30–90 minutes) and longer duration (4–6 hours), useful for persistent symptoms. Sublingual tinctures shorten onset relative to edibles while maintaining extended relief.

Potential Medical Uses

CBD-dominant cannabis is commonly used by patients for anxiety, stress, and mood regulation, with published cohorts reporting notable improvements. In one real-world series of 72 adults using CBD for anxiety and sleep, 79.2% experienced reduced anxiety within the first month and 66.7% saw sleep improvements, though individual responses varied and some tolerance effects were noted over time.

CBD has also demonstrated anti-seizure efficacy in randomized controlled trials for specific epileptic syndromes, supporting its FDA-approved use as purified CBD in certain contexts. While whole-plant flower is not a substitute for prescription formulations, patients with seizure histories often prefer CBD-dominant profiles and should coordinate with clinicians.

For pain, meta-analyses indicate modest average reductions in chronic and neuropathic pain intensity with cannabinoid therapies, typically on the order of 0.5–1.0 points on a 0–10 scale across studies. CBD’s role may be more pronounced in inflammatory pain due to CB2-linked mechanisms via beta-caryophyllene and non-cannabinoid receptor targets (TRPV1, 5-HT1A), though effects are generally milder than high-THC analgesia.

Inflammation, muscle tension, and recovery are frequent use cases reported by athletes and older adults. A 2021 survey of active adults found over 60% using CBD for exercise recovery and sleep, with subjective improvements in soreness and relaxation—results that are promising yet still rely on self-report.

Typical starting doses for inhalation are 1–3 gentle puffs, approximating 5–15 mg CBD depending on device efficiency and potency. For oral use, 10–25 mg CBD is a reasonable entry point, titrating by 5–10 mg increments every 2–3 days while monitoring for drowsiness or GI upset.

Comprehensive Cultivation Guide

Genetics and seed selection: When sourcing Celestial - Suzy QFX Harli-Tsu BX1 M, clarify whether you are receiving regular seeds from the BX1 male line, feminized derivatives, or a verified female clone. Regular seeds will segregate male and female; breeders may prefer this for selecting vigorous CBD-dominant parents.

Expected morphology: Plants average medium height with 1.5× stretch after flip. Internodes are moderate, making them responsive to topping and low-stress training (LST).

Environment: Target 24–28°C daytime and 18–22°C nighttime during veg and early flower. In late flower, a 2–3°C drop helps color expression and resin maturation without slowing metabolism excessively.

Humidity and VPD: Maintain 60–70% RH in seedlings, 50–60% in veg, 45–50% in early flower, and 40–45% in late flower. Managing vapor pressure deficit (VPD) around 0.8–1.1 kPa in veg and 1.2–1.5 kPa in flower will balance growth and disease suppression.

Lighting: Aim for PPFD of 300–400 µmol/m²/s for early veg, 500–700 for late veg, and 800–1,000 in flower, with a daily light integral (DLI) of ~35–45 mol/m²/day by mid-flower. Ensure uniformity and adequate CO2 (ambient 400–800 ppm is sufficient) to prevent light stress.

Photoperiod: Use 18/6 for veg and 12/12 for flower. Flowering time is typically 56–65 days, with some phenotypes finishing closer to day 63–67 for maximum CBD.

Medium and pH: In living soil, maintain pH 6.2–6.8 with ample Ca/Mg and organic matter >5%. In coco/hydro, target root-zone pH 5.8–6.2 and monitor runoff EC to avoid salt buildup.

Nutrition targets (coco/hydro per week averages): Provide 100–130 ppm N in veg and 80–100 ppm N in early flower, tapering to ~70 ppm in late flower. Keep P ~50–70 ppm, K ~200–280 ppm, Ca ~150 ppm, and Mg ~50–70 ppm, with S ~60–90 ppm; adjust based on leaf tissue tests.

Organic strategy: Top-dress with balanced amendments (e.g., 2-5-2) at flip and week 3, plus gypsum for Ca/S and basalt or basalt/greensand for K and trace minerals. Supplement with kelp and amino-acid foliar sprays in early veg for micronutrients and stress resilience.

Irrigation: In coco, water to 10–20% runoff to keep EC stable, allowing only slight dry-back. In soil, employ a pulse-watering rhythm that keeps media at 25–35% volumetric water content; avoid big swings that invite calcium transport issues.

Training: Top at the 5th node and run a double-top or FIM to create 6–10 strong mains, then SCROG to spread the canopy. Expect 1.3–1.7× stretch; set your trellis before flip and a second layer by week 2–3 of flower for support.

IPM: This line has moderate resistance to botrytis due to its not-too-dense flowers, but it can show average susceptibility to powdery mildew under high humidity and stagnant air. Use good airflow, leaf sanitation, and weekly soft IPM (e.g., Beauveria bassiana, Bacillus subtilis, potassium bicarbonate rotations) through week 2–3 of flower.

Defoliation and airflow: Conduct a light defoliation at day 21 of flower to open interior sites, then a clean-up at day 42 if needed. Avoid over-stripping; CBD production thrives with generous solar area.

Yield expectations: Indoors, anticipate 400–550 g/m² under efficient LEDs at 800–1,000 PPFD with proper training. Outdoors in full sun, 1.5–2.5 kg per plant is achievable with 100–200 gallon containers, strong soil biology, and diligent IPM.

Harvest timing: CBD and THC typically rise together until plateau; peak CBD often occurs slightly before peak THC oxidation. If you cannot lab test, harvest at mostly cloudy trichomes with minimal amber (e.g., <10% amber heads) around day 58–63 for a bright CBD effect.

Dry and cure: Aim for a slow dry of 10–14 days at 60°F and 55–60% RH until stems snap. Cure in airtight containers burped to maintain 58–62% RH, targeting water activity between 0.55–0.65 for shelf stability and terpene preservation.

Compliance: If producing hemp-compliant material, test early and often; total delta-9 THC must remain at or below legal thresholds per local regulations. Field sampling around weeks 4–6 provides an early warning if the crop trends hot, allowing an earlier harvest to stay compliant.

Breeding With the BX1 Male (M)

The “M” designation indicates a selected male, which is central to how this line is leveraged in breeding. A CBDAS/CBDAS (BD/BD) male crossed to a CBDAS/CBDAS female produces 100% Type III (CBD-dominant) offspring in simple Mendelian models.

When a BD/BD male is crossed to a BT/BT THC-dominant female, all progeny are BT/BD heterozygotes and tend toward Type II (balanced) chemotypes unless other loci influence expression. Crossing BD/BD to BT/BD can yield a 1:1 mix of Type II and Type III, though real-world outcomes are modulated by regulatory and expression factors.

Use qPCR or targeted sequencing to confirm CBDAS vs THCAS allele presence in parents before scaling seed production. Phenohunt for terpene synergy—prioritize pinene/caryophyllene continuity for daytime CBD effects while avoiding phenotypes that drift toward excessive terpinolene if sedation is undesirable.

For hash-focused breeding, select for gland head size and resin yield under microscope assessment. CBD-dominant lines can produce 4–6% hash yield (ice water) from dried material, with 73–120 µ fractions offering the best balance of flavor and effect; rosin returns from quality flower commonly range 15–22%.

Use Cases and Consumption Tips

For daytime calm without intoxication, a single small joint or 1–3 short vaporizer pulls is usually sufficient. This typically delivers 5–15 mg CBD depending on potency and device efficiency.

For persistent discomfort, microdosing multiple times across the day (e.g., every 2–3 hours) maintains a stable baseline. Evening use can be slightly heavier to leverage myrcene’s somatic relaxation without grogginess.

Combining with small amounts